Abstract: Etravirine is a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) that is approved for the treatment of adult human immunodeficiency virus (HIV)-infected patients with documented or suspected resistance to first-generation NNRTIs. Etravirine has a flexible molecular structure that allows it to retain its activity against mutant HIV strains that exhibit resistance to first-generation agents. It is evident that 3 or more etravirine resistance-associated mutations are typically necessary before clinical resistance to etravirine. Safety and efficacy of etravirine are established in antiretroviral treatment-experienced patients in combination with antiretroviral regimens that contain darunavir/ritonavir. In phase III studies, cutaneous reactions occurred in 19% of treated patients and are the most commonly observed adverse event. The typical manifestation is the development of a maculopapular rash within the first few weeks of etravirine therapy. Resolution commonly occurs within 1-2 weeks on continued therapy. Rare cases of severe skin reactions (,0.1%) have been reported. Etravirine is hepatically metabolized by cytochrome P450 (CYP) 3A4, CYP2C9, and CYP2C19. Drug interactions with some antiretrovirals (eg, unboosted protease inhibitors and fosamprenavir/ ritonavir) and medications for other comorbidities (eg, atorvastatin and clarithromycin) have been reported and may require dosage adjustment for the coadministered drug or selection of alternative therapy in some instances. Administration of etravirine with potent inducers of CYP450 is not recommended due to the potential for subtherapeutic etravirine concentrations. In this article, the pharmacology, efficacy, safety, and tolerability of etravirine in adult treatmentexperienced patients with HIV-1 infection are reviewed. Medical literature was identified by MEDLINE and EMBASE searches (1966 to February 2010) using the search terms "etravirine", "TMC125", and "NNRTI".
Introduction
It is estimated that 33.4 million people globally were living with human immunodeficiency virus (HIV) infection, with approximately 2.7 million new infections per year as of 2008. Two million deaths are attributed to HIV infection each year, 280,000 of which are in children younger than 15 years. 1 Of the estimated 9.5 million HIV-infected individuals in developing and transitional countries, 42% have access to antiretroviral therapy, resulting in declining rates of mortality due to the acquired immune deficiency syndrome (AIDS). 1 In the United States, approximately 56,300 new infections occur each year. 2 AIDS-related mortality has declined in the United States since 1996 with the introduction of highly active antiretroviral therapy. 3 HIV infection is now managed as a chronic infection, requiring life-long antiretroviral therapy to improve and sustain immune function. The use of combination therapy with 3 or more antiretrovirals represents the current standard of care for the treatment of HIV infection. Protease inhibitors and nonnucleoside reverse transcriptase inhibitors (NNRTIs) are presently recognized as preferred agents for treatment of patients without prior antiretroviral treatment experience. [4] [5] [6] Integrase inhibitors have recently been added as another preferred option in some instances. 4 Selection of protease inhibitor-, NNRTI-, or integrase inhibitor-based antiretroviral therapy is based on regimen potency, potential for resistance, drug interaction potential, and adherence considerations. In treatmentexperienced patients, selection of antiretrovirals is based on the presence of documented or suspected resistance. [4] [5] [6] A summary of approved antiretrovirals and recommended antiretroviral regimens for treatment-naive patients is shown in Figure 1 .
The NNRTIs were first introduced in 1996 and are widely used as initial therapy for therapy-naive patients due to their simplicity in dosing and overall favorable tolerability profile; however, they are susceptible to the rapid emergence of drug resistance during therapy, particularly if patients are nonadherent. 7 In addition, de novo resistance to antiretroviral therapy has been observed in up to 20%-24% of patients, including first-generation NNRTIs (efavirenz, nevirapine, and delavirdine), before beginning treatment. 8 Therefore, a significant need has existed to identify new NNRTI compounds that retain their activity in the presence of mutant HIV strains that harbor resistance to first-generation agents. The discovery Recommended antiretroviral regimens for treatment-naïve patients [4] [5] [6] Non-nucleoside reverse transcriptase inhibitor +2 nucleoside reverse transcriptase inhibitors 
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etravirine in the treatment of HiV-1 infection and synthesis of etravirine are the culmination of 15 years of exploration to identify compounds with activity against both wild-type and mutant HIV strains exhibiting resistance to early generation NNRTIs. 9 Etravirine was approved for use in the United States and Europe in 2008 and represents the first second-generation NNRTI. This article reviews the pharmacology, efficacy, safety, and tolerability of etravirine in adult treatment-experienced patients with HIV-1 infection. Medical literature was identified by MEDLINE and EMBASE searches (1966 to February 2010) using the search terms "etravirine", "TMC125", and "NNRTI". Additional references were obtained from reference lists of published articles and by reviewing meeting abstracts. The manufacturer was also contacted to provide unpublished data.
Pharmacology

Mechanism of action
HIV reverse transcriptase is responsible for the transcription of single-stranded viral RNA into single-stranded DNA, which is eventually integrated into the host DNA as double-stranded DNA. Like other NNRTIs, etravirine is a noncompetitive inhibitor of HIV reverse transcriptase and binds to subunit p66 of reverse transcriptase, resulting in a conformational change in the catalytic site for reverse transcriptase that limits its activity. 10 11 Etravirine has a flexible molecular structure, allowing it to bind to multiple conformations in a hydrophobic binding pocket adjacent to the catalytic site of reverse transcriptase and retain its activity in the presence of mutations that confer resistance to first-generation NNRTIs. 10, 12 The structure of etravirine and other currently available NNRTIs is depicted in Figure 2 .
Etravirine exhibits potent in vitro activity against wild-type HIV-1 strains, with median 50% effective concentrations (EC 50 ) ranging from 1.4 to 4.8 nmol/L that are comparable to the activity of efavirenz (1.2-3.4 nmol/L).
11
Similar activity is observed against first-generation NNRTIresistant virus (EC 50 # 10 nM for 83% of 6,171 recombinant clinical isolates tested) as well as non-clade B and circulating recombinant strains that are becoming more prevalent due to immigration and heterosexual transmission. 11, 13 Unlike other NNRTIs, etravirine also demonstrates weak activity against HIV-2 strains, with an EC 50 of 3.5 µM; however, this is not believed to be clinically relevant. 
94
Rathbun and Liedtke
Pharmacokinetics
The pharmacokinetics of etravirine are based on studies utilizing 3 oral formulations: the polyethylene glycol (PEG) 4000-based 50 mg capsule (TF002) as etravirine base used in early phase I and phase IIa studies, the hydroxypropylmethylcellulose (HPMC) 200 mg tablet formulation (TF035) as etravirine hydrogen bromide salt used in late phase I and phase II studies, and the spray-dried HPMC 100 mg tablet formulation (F060) as amorphous etravirine base as the current commercial product used in phase III trials. Formulation modifications were made to improve bioavailability due to the poor solubility exhibited by etravirine and to reduce tablet size. 13 A 25 mg spray-dried HPMC tablet is currently being investigated for children and adolescents. 14 Etravirine is slowly absorbed, with peak plasma concen trations achieved after approximately 4 hours (range, 2-8 hours) with the current commercial formulation. 15 Although the oral bioavailability of etravirine has not been established, administration with food increases apparent bioavailability by up to 50% and decreases intersubject variability. Significant differences in absorption are not evident with varying food compositions. 16 Two hundred milligrams of the F060 amorphous tablet formulation used commercially achieves 30%-70% higher systemic exposure compared with 800 mg of the TF035 hydrogen bromide salt used in phase II studies. 13 Use of acid suppressants (eg, antacids, H2 receptor antagonists, and proton pump antagonists) does not alter etravirine absorption; although coadministration with omeprazole does increase etravirine systemic exposure, presumably due to impaired CYP2C19 metabolism. 17 Dispersion of F060 tablets in a glass of water prior to ingestion does not result in reduced bioavailability and represents an alternative oral administration option.
14 Serum concentrations decline with repeated dosing due to autoinduction of metabolism. 13 The elimination half-life for etravirine is approximately 30-40 hours. Interpatient and intrapatient variability in pharmacokinetics in HIV-infected patients are 60% and 40%, respectively. 15 Higher etravirine systemic exposure is noted with decreased body weight and hepatitis B or C coinfection (1.35-fold) but does not warrant dosage modification. 18 Serum concentrations achieved in patients with mild-to-moderate hepatic impairment (Child-Pugh class A or class B) are similar to healthy subjects and do not require dosage adjustment. 19 In a single case of a woman with decompensated liver disease, etravirine serum concentrations were 60-fold higher than projected on standard dosing, with an estimated half-life of 237 hours, indicating that etravirine should be avoided in patients with severe hepatic impairment (Child-Pugh class C). 20 Etravirine is 99.9% bound to plasma protein, primarily to albumin and alpha 1 -acid glycoprotein, in a concentration-independent manner.
14 Modest reduction (29%) in etravirine serum concentration was observed in a single patient receiving hemodialysis 3 times weekly on standard etravirine doses, signifying that dosage modification with dialysis is not likely necessary. 21 The extent of etravirine distribution into the central nervous system and other tissues has not been fully characterized. 13, 14 A summary of etravirine pharmacokinetics is given in Table 1 .
Metabolism and drug interactions
Etravirine is metabolized by cytochrome P450 (CYP) 3A4, CYP2C9, and CYP2C19 and has the potential for drug interactions with coadministered medications. It exhibits a mixed interaction profile, as illustrated by its potential to induce CYP3A4, CYP2B6, and uridine diphosphateglucuronosyltransferase and inhibits CYP2C9 (inhibition constant [K i ] = 0.25 µg/mL) and CYP2C19. 13 Etravirine is also an inhibitor of p-glycoprotein, with an apparent 50% inhibition concentration (IC 50 ) of 24.2 µM. Low amounts of etravirine (1.2%) are eliminated in urine; over 80% of an administered dose is excreted unchanged in the feces. 13 Drug interactions between etravirine and some antiretrovirals have been described. Etravirine decreases unboosted atazanavir, indinavir, and saquinavir and should not be used with these agents in the absence of ritonavir.
14 Etravirine also decreases atazanavir boosted with low-dose ritonavir, but the clinical significance of this is unknown. 22 Amprenavir systemic exposure is increased with etravirine; therefore, caution should be exercised in using combined etravirine and fosamprenavir/ritonavir therapy. 23 Tipranavir/ritonavir significantly lowers etravirine serum concentrations (70%-80%) and should not be used concurrently. 24 Etravirine can be safely used in combination with lopinavir/ritonavir, 
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etravirine in the treatment of HiV-1 infection ritonavir-boosted darunavir, and saquinavir.
14 Concurrent use of etravirine with other NNRTIs has not been shown to be beneficial and is not recommended; reduction in etravirine serum concentrations is anticipated if combined with either efavirenz or nevirapine. 13, 25 No clinically significant interactions between etravirine and tenofovir and didanosine have been identified. 26, 27 Interactions with other nucleoside reverse transcriptase inhibitors (NRTIs) are not expected to occur. 13 Etravirine reduces serum concentrations of the CCR5 receptor antagonist, maraviroc, and requires different dosage adjustments based on whether a boosted protease inhibitor is included in the regimen. 28 Minimum concentrations of the integrase inhibitor, raltegravir, are lower with concurrent etravirine in healthy volunteers and were associated with decreased virologic response in 4 HIV-infected patients; however, the clinical relevance of this is uncertain. [29] [30] [31] Interactions between etravirine and medications for other comorbidities have also been described. Etravirine decreases the concentrations of clarithromycin, atorvastatin, and sildenafil and may require the use of higher doses of these agents or selection of alternative therapy. [32] [33] [34] The use of etravirine with other statins (eg, simvastatin and lovastatin) and phosphodiesterase-5 inhibitors (taladafil and vardenafil) has not been studied but may require dosage adjustments with some agents due to similar metabolism through CYP3A4. 35 Digoxin serum concentrations are increased by etravirine, potentially due to the inhibition of p-glycoprotein, but are not thought to be clinically significant. 36 A 35% reduction in etravirine area under the curve (AUC) occurs with rifabutin but is not thought to be clinically significant unless a boosted protease inhibitor is also coadministered. 37 Administration of etravirine with potent enzyme inducers (eg, rifampin, phenytoin, phenobarbital, and carbamazepine) is not recommended due to the potential for subtherapeutic etravirine concentrations. 35 In studies conducted in healthy volunteers, etravirine increased single-dose warfarin 10 mg (S-warfarin AUC ratio with and without etravirine = 1.05; 90% confidence interval, 0.93-1.19), indicating that etravirine has the potential to alter warfarin metabolism by inhibition of CYP2C9. 38 The labeling of etravirine was recently updated to include information regarding interactions with fluconazole, voriconazole, and clopidogrel. 35 Coadministration of fluconazole or voriconazole with etravirine significantly increased the etravirine concentrations. The clinical implications of this increase are unknown and, as such, these combinations should be used with caution. Inhibition of 2C19 by etravirine may decrease the concentration of the active metabolite of clopidogrel and, therefore, decrease its therapeutic effect. Use of an alternate agent is suggested. A summary of the effect of etravirine on coadministered drugs is given in Table 2 . 
Resistance
Etravirine exhibits a higher genetic barrier to resistance than other NNRTIs because 3 or more resistance-associated mutations (RAMs) are typically necessary to cause clinical resistance vs a single mutation with first-generation NNRTIs. [39] [40] [41] In addition, presence of the K103N (lysine to arginine) mutation that commonly confers resistance to first-generation NNRTIs is not associated with decreased virologic response to etravirine. 42 Seventeen RAMs have been associated with decreased susceptibility to etravirine. The magnitude of resistance is determined by the number and the weighted genotype mutation score for individual mutations; an example of the DUET weighted score is outlined in Table 3 . 42 Some discordance in etravirine susceptibility interpretation currently exists between different genotype algorithms and may be related to variations in mutation selection criteria and weight assignment for individual mutations (eg, Y181C and L100I). 43 Summation of weighted mutation scores has been correlated with clinical response, where DUET weighted scores of 0-2 were associated with a 74% virologic response rate, whereas scores of 2.5-3.5 and $4.0 were associated with viral response rates of 52% and 38%, respectively. 42 The highest change in EC 50 occurs with the combination of V179F with either Y181C or Y181I. 13 The prevalence of baseline clinical resistance to etravirine among patients leading to NNRTI treatment failure ranges from 4.6% to 13%. [44] [45] [46] [47] Failure of nevirapine therapy is associated with a greater likelihood for the development of etravirine RAMs compared with the failure of efavirenz. 44, [46] [47] [48] Patients with less than 3-fold change in EC 50 are more likely to achieve viral suppression with etravirine than patients above this threshold, which is used as the lower cutoff for phenotypic resistance assays; a $13-fold reduction in phenotypic susceptibility represents the upper clinical cutoff and is associated with the absence of clinical response to etravirine.
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Clinical efficacy
The clinical efficacy of etravirine in adult HIV-infected patients has been established based on results from phase II and phase III studies. These studies examined the use of etravirine in antiretroviral treatment-experienced patients and in treatment-naive subjects. The efficacy of etravirine in special populations (pregnant women and pediatric patients) in well-controlled studies is currently being investigated.
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Proof of principle studies (phase IIa)
TMC125-C208 was a randomized, double-blind, placebocontrolled trial to assess the short-term antiviral activity, safety, tolerability, and pharmacokinetics of etravirine monotherapy in treatment-naive and HIV-infected individuals. Nineteen subjects were randomized 2:1 to receive etravirine 900 mg as PEG 4000 capsule formulation or placebo. Patients received medication twice daily for 7 days within 15 minutes of a meal. The primary efficacy parameter was the change in plasma HIV-1 RNA from baseline. Tolerability and safety were evaluated using patient-reported adverse effects and laboratory changes. After 7 days of treatment, a mean decrease in plasma HIV-1 RNA of 1.99 log 10 copies/mL was observed (range, 3.39-1.13) in patients receiving etravirine compared with 0.06 log 10 copies/mL in the placebo group. Viral decay was calculated at a rate of 0.33 log 10 copies/mL per day in the treatment group compared with 0.02 log 10 copies/mL per day in the placebo group (P , 0.001). All subjects in the etravirine treatment arm achieved $1 log 10 reduction in viral load; 8 subjects achieved a plasma HIV-1 RNA , 400 copies/mL (P , 0.001) and 2 were , 50 copies/mL (P = NS). Patients receiving etravirine also had a significant increase in CD4 cells compared with the placebo group (+104 and −150 cells/µL, respectively; P = 0.016).
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TMC 125-C207 was an open-label study on the efficacy, tolerability, safety, and pharmacokinetics of etravirine monotherapy in HIV-1-infected subjects who fail a current NNRTI-containing regimen. Sixteen patients on an NNRTIcontaining regimen (efavirenz or nevirapine) with plasma HIV-1 RNA . 2,000 copies/mL and confirmed phenotypic resistance to efavirenz were included in the study. Patients were given etravirine 900 mg PEG 4000 capsule twice daily for 7 days. Antiretroviral therapy selected on the basis of resistance testing obtained during study screening was initiated on day 8. The primary outcome measure was the mean plasma HIV-1 RNA decay rate over the 7-day treatment period. Fifteen patients completed the study. A plasma HIV-1 RNA decay rate of 0.13 log 10 copies/mL per day was observed during the treatment period (P , 0.001). Viral load decrease ranged from 0.18 to 1.71 log 10 copies/mL with a median decrease of 0.89 log 10 copies/mL. Seven (44%) patients had a decrease in viral load of at least 1.0 log 10 and 12 (75%) had a decrease The relative weight assigned to each individual mutation signifying the magnitude of change in susceptibility using the DUeT weighted score. 42 Cumulative scores greater than 4 are associated with the lowest virologic response to etravirine. 
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etravirine in the treatment of HiV-1 infection of at least 0.5 log 10 . Two patients achieved plasma HIV-1 RNA , 400 copies/mL. There were no significant changes in either mean CD4 count or CD4 percentage. The extent of resistance to efavirenz and etravirine at baseline was 116.1-fold and 2.2-fold, respectively. At the end of therapy, no new NNRTIassociated resistance mutations were identified. 51 Dose-ranging studies (phase IIb) TMC 125-C203 was a 48-week, double-blind, placebocontrolled, 2-stage dose escalation study conducted in HIV-1-infected subjects with prior NRTI, protease inhibitor, and NNRTI experience. Patients were randomly assigned to the 400, 800, and 1,200 mg TF035 tablet formulations of etravirine administered twice daily or to placebo, in combination with optimized background therapy (OBT). Patients enrolled in stage 1 were randomized in a 1:1:1 fashion to receive etravirine 400 mg, etravirine 800 mg, or placebo twice daily. Patients enrolled in stage 2 were randomized in a 1:2:4 manner to receive placebo, etravirine 800 mg, or etravirine 1,200 mg administered twice daily. The primary end point was safety over 48 weeks; plasma HIV-1 RNA measurements were collected and reported but could not be reliably interpreted due to the modification of viral load collection technique during the study. A total of 240 patients were enrolled in the trial (166 patients in stage 1 and 74 patients in stage 2), with 57, 74, 43, and 66 subjects enrolled in the 400, 800, 1,200 mg, and placebo arms, respectively, for the initial 48-week period. 13 Patients were allowed to extend treatment beyond 48 weeks. More patients in the etravirine group received de novo enfuvirtide as OBT. Viral load results were reported only for samples collected using EDTA tubes. No significant difference in viral load reduction was noted between the combined etravirine groups and placebo group during stage 1 at weeks 24 and 48; however, a significant difference was observed at week 24 in the 800 mg and 1,200 mg etravirine groups compared with placebo (P = 0.009 and P = 0.049, respectively). Similarly, no significant differences in CD4 change were noted between groups in stage 1. Significant differences between the 800 mg and 1,200 mg etravirine groups and the placebo group were observed during stage 2 (P = 0.025 and P = 0.019, respectively). CD4 changes were also greater in the 2 etravirine groups (P = 0.025 and P = 0.019 for the 800 mg and 1,200 mg groups, respectively, compared with placebo). No difference in safety was noted between the etravirine groups and the placebo group. 52 TMC 125-C223 was a 48-week, partially blinded, controlled, multicenter, dose-ranging trial conducted in 199 treatment-experienced HIV-1-infected subjects with baseline NNRTI resistance and 3 or more primary protease inhibitor mutations. Patients were randomized in a 1:2:2 fashion to the active control group or etravirine 400 mg or 800 mg TF035 tablet formulation given twice daily. Investigators and study subjects were blinded to etravirine dose but not to assignment to etravirine therapy or control. Antiretroviral therapy in the control arm consisted of at least 3 approved antiretrovirals that included NRTIs, protease inhibitors, and enfuvirtide or a combination of all 3. Patients assigned to the 2 etravirine groups also received investigator-selected OBT consisting of at least 2 approved antiretrovirals that included NRTIs, lopinavir/ritonavir or enfuvirtide, or a combination of all 3. The primary end point was the mean change in plasma HIV-1 RNA from baseline. A total of 199 patients (n = 80 etravirine 400 mg, n = 79 etravirine 800 mg, n = 40 placebo) were randomized and included in the intent-to-treat analysis. At 48 weeks, the mean change in plasma HIV-1 RNA was −0.88, −1.01, and −0.14 log 10 copies/mL in the etravirine 400, 800 mg, and control groups, respectively (P = 0.018 and P = 0.002 for the 400 mg and 800 mg groups, respectively, compared with control). The proportion of patients achieving plasma HIV-1 RNA , 50 copies/mL was 22.5% and 21.5% in the 400 mg and 800 mg etravirine groups, respectively, vs none in the control group (P , 0.001). From subgroup analysis, greater reduction in viral load was achieved in patients receiving etravirine 800 mg vs 400 mg twice daily when either enfuvirtide or a protease inhibitor were not included in the regimen. Greater response with 800 mg etravirine twice daily was also observed with increased number of active agents in the regimen. The number of etravirine RAMs at baseline was predictive of response to etravirine, with the greatest reductions in viral load occurring in patients with the fewest mutations. CD4 cell count increases appeared to be greater in the etravirine groups compared with the control group but did not achieve statistical significance. A large number of patients (n = 100) discontinued the study prematurely due to virologic failure, with a greatest proportion occurring in the control group (97.5%) compared with the combined etravirine arms (38.4%). Given the greater virologic response with the 800 mg vs 400 mg etravirine dose in the absence of concomitant enfuvirtide use and no apparent differences in safety, the 800 mg dose was selected for further phase III studies. 53, 54 TMC125-C227 was a randomized, controlled, open-label, exploratory study in protease inhibitor-naive patients with documented NNRTI resistance. Eligibility criteria included plasma HIV-1 RNA $ 1,000 copies/mL. Women who had developed NNRTI resistance as a result of receiving previous NNRTI treatment to prevent mother to child HIV transmission were allowed to participate and comprised 25% of the study population. Patients with chronic hepatitis B or C infection could participate if liver transaminases were less than 3 times the upper limit of normal. Patients were randomly assigned (1:1) to etravirine TF035 formulation 800 mg twice daily or to an investigator-selected protease inhibitor, both in combination with 2 NRTIs selected by the investigator. A total of 116 patients (n = 59 etravirine, n = 57 control) were included in the intent-to-treat population. Ninety-six percent of patients in the control group received a ritonavir-boosted protease inhibitor. An unplanned interim analysis was conducted at week 12 and showed a change in mean plasma HIV-1 RNA of −1.39 log 10 in the etravirine group vs −2.16 log 10 in the control group, indicating that virologic response in the etravirine arm was inferior. CD4 response was similarly lower in the etravirine group compared with controls at week 12 (42 and 79 cells/mm 3 , respectively). Enrollment in the etravirine arm was subsequently discontinued, and patients originally assigned to etravirine treatment were switched to investigator-selected protease inhibitor therapy for the remaining duration of follow-up. Post hoc analysis of treatment response based on baseline resistance showed that a greater proportion of patients in the etravirine group had preexisting NRTI resistance, including thymidine analog mutations, M184I/V, and K65R. Thirtyone percent of etravirine patients had no active NRTIs in their antiretroviral regimen compared with 23% of control patients. Although the presence of any NNRTI RAM at baseline was also associated with reduced virologic response, the number of mutations did not predict response unless the mutations were etravirine RAMs. Presence of 3 or more etravirine RAMs was associated with the greatest reduction in virologic response, especially when Y181C was present. Patient who showed increased virologic response were more likely to have an etravirine phenotypic fold-change less than 4 (−1.82 log 10 ; n = 24) at baseline compared with those with a fold change greater than 4 (−0.96 log 10 ; n = 11). Although viral load reductions were numerically greater in patients with etravirine AUC 12 exceeding 4,521 ng⋅h/mL, no significant relationship between viral load response and etravirine systemic exposure was noted. 55 The ANRS 139 TRIO study was a multicenter, uncontrolled trial assessing the efficacy and safety of antiretroviral regimens containing etravirine, darunavir/ritonavir, and raltegravir in antiretroviral treatment-experienced patients in 49 clinics in France. Eligibility criteria included plasma HIV-1 RNA . 1,000 copies/mL, $3 protease inhibitor mutations, and $3 NRTI mutations. Patients with a history of virologic failure during treatment with a first-generation NNRTI were also eligible provided in vitro susceptibility to etravirine was evident at screening. Patients with chronic hepatitis B or C infection with Child-Pugh scores of B or C without cirrhosis or liver function tests less than 3 times the upper limit of normal were also included. Etravirine 200 mg twice daily using the F060 tablet formulation was administered with raltegravir 400 mg twice daily and darunavir/ritonavir 600/100 mg twice daily. OBT consisted of investigator-selected NRTIs with or without enfuvirtide. The primary end point was the proportion of patients with plasma HIV-1 RNA , 50 copies/mL at week 24; secondary end point included the proportion of patients with plasma HIV-1 RNA , 50 copies/mL at week 48. A total of 103 patients were enrolled in the study and comprised the intent-to-treat population. One hundred patients (97%) remained on therapy at week 24. The median duration of prior antiretroviral therapy for the study population was 13 years. Viral suppression to ,50 copies/mL was observed in 90% of patients at week 24 and 86% of patients at week 48. Five of the 10 patients with plasma HIV-1 RNA . 50 copies/mL had viral loads ,400 copies/mL. Eighty-four percent of patients in the study received NRTIs as their OBT; 12% had enfuvirtide included in their OBT. The median changes in viral load and CD4 at week 48 were −2.4 log 10 and +108 cells/ mm 3 , respectively. 56 Large safety and efficacy studies (phase III)
The efficacy and safety of etravirine in antiretroviral treatment-experienced patients with preexisting NNRTI resistance have been established on the basis of 2 large multicenter phase III clinical trials (DUET 1 and DUET 2) with identical study designs.
TMC125-C206 (DUET 1) was a randomized, doubleblind, placebo-controlled trial conducted in South America, Mexico, Puerto Rico, Panama, Thailand, France, and the United States. Inclusion criteria included a plasma HIV-1 RNA $ 5,000 copies/mL, presence of $3 primary protease inhibitor mutations, and at least 1 NNRTI RAM. Patients with chronic hepatitis B and C coinfection were permitted to enroll, provided liver transaminases were within 5 times the upper limit of normal and treatment was not thought to be necessary by the investigator. Study subjects were randomly assigned (1:1) to etravirine 200 mg using the 100 mg F060 tablet formulation or placebo twice daily in combination with low-dose ritonavir-boosted darunavir and investigator-selected NRTIs. Use of enfuvirtide was optional. Randomization was stratified according to use or reuse of enfuvirtide, prior darunavir use, and baseline plasma HIV-1 RNA $ 30,000 copies/mL. The primary end point was the proportion of patients with plasma HIV-1 RNA , 50 copies/mL at 24 weeks. A total of 612 patients (n = 304 etravirine, n = 308 placebo) were included in the intent-to-treat population. After 24 weeks of therapy, 56% and 39% of patients in the etravirine and placebo groups, respectively, achieved plasma HIV-1 RNA , 50 copies/mL (P = 0.005). Plasma HIV-1 RNA decreased from baseline by a mean of 2.41 log 10 copies/mL compared with 1.70 log 10 copies/mL in the 2 treatment arms, respectively (P , 0.0001). CD4 cell counts increased from baseline by 89 cells/mm 3 in the etravirine arm and 64 cells/mm 3 in the placebo arm (P = 0.0002). Patients who reused or did not use enfuvirtide were more likely to achieve a plasma HIV-1 RNA , 50 copies/mL in the etravirine arm than in the placebo arm (55% and 33%, respectively; P , 0.0001 for the difference). However, no significant difference in the proportion of patients achieving the primary end point was observed between the groups with de novo enfuvirtide use. TMC125-C216 (DUET 2) was a randomized, doubleblind, placebo-controlled trial conducted in Australia, Canada, Europe, Poland, Portugal, and the United States. Inclusion criteria, assignment to therapy, and prespecified analyses were identical to DUET 1. A total of 591 patients (n = 295 etravirine, n = 296 placebo) comprised the intent-to-treat population. After 24 weeks of therapy, 62% and 44% of patients in the etravirine and placebo groups, respectively, achieved plasma HIV-1 RNA , 50 copies/mL (P = 0.0003). Plasma HIV-1 RNA decreased from baseline by 2.34 log 10 copies/mL compared with 1.68 log 10 copies/mL in the 2 treatment arms, respectively (P , 0.0001). CD4 cell counts increases between the 2 groups were not significantly different. Greater virologic suppression was observed in the etravirine group than in the placebo group, regardless of the number of active drugs in the accompanying antiretroviral regimen. However, no significant difference in the proportion of patients with plasma HIV-1 RNA , 50 copies/mL or ,400 copies/mL was present when de novo enfuvirtide was controlled for in the 2 study groups. The 2 groups were well balanced regarding enfurvirtide use, with 27% receiving enfuvirtide de novo and 25% reusing it in both groups. 40 Virologic response to etravirine was sustained beyond the initial 24 weeks of therapy. In the pooled DUET-1 and DUET-2 preplanned analysis, 61% of patients in the combined etravirine group had plasma HIV-1 RNA , 50 copies/mL compared with 40% of patients in the combined placebo group at week 48. Plasma HIV-1 RNA decreased by 2.25 log 10 copies/mL and 1.49 log 10 copies/mL in the etravirine and placebo groups, respectively (P , 0.0001). CD4 cell counts increased from baseline by 98 cells/mm 3 vs 73 cells/mm 3 in the etravirine and placebo groups, respectively (P = 0.0006). By week 48, the pooled etravirine group vs the placebo group achieved higher virologic responses regardless of the number of active agents used in the background regimen. 37, 38 At 96 weeks, 57% vs 36% had plasma HIV-1 RNA , 50 copies/mL in the etravirine and placebo groups, respectively (P , 0.0001), demonstrating long-term efficacy with etravirine. 57 
Adverse events
The most common adverse events associated with etravirine occurring at a higher rate than placebo are the development of cutaneous reactions (19%). Cutaneous reactions typically manifest as a maculopapular rash after a median of 14 days and are mild to moderate in severity. In phase III studies, 1.3% of patients developed grade 3 or 4 rashes while receiving etravirine vs 0.2% receiving placebo. Overall, 2.2% of patients in phase III trials discontinued therapy because of rash. The majority of rashes occurred within the first 4 weeks of therapy. Resolution is reported to occur within 1-2 weeks (median, 15 days) on continued therapy. Women appear to be at greater risk than men (30% vs 18% frequency of rash in women and men in the DUET studies, respectively); however, the severity of rash does not appear to differ. History of a rash with other NNRTIs is not predictive of the risk for cutaneous reactions with etravirine. 58 In postmarketing reports, rare cases (,0.1%) of severe, life-threatening skin reactions (StevenJohnson syndrome, toxic epidermal necrolysis, and erythema multiforme) have prompted revised safety labeling. 35 These reactions have included rash, constitutional symptoms, and occasionally include organ dysfunction (eg, hepatic failure). Gastrointestinal effects are primarily nausea (14%), diarrhea (19%), and abdominal pain that are mild in severity. No significant changes in adverse event profile were notable in patients who continued etravirine therapy to 48 or 96 weeks. 58, 59 Etravirine does not exhibit significant potential to alter cardiac conduction. A randomized, double-blind, placebo/activecontrolled study in 41 HIV-seronegative volunteers showed no prolongation of QTc interval. 60 Etravirine has also not been demonstrated to cause birth defects in animal studies and is labeled as pregnancy category B. However, because safety has not been established in infants, women should not breastfeed while receiving etravirine. 35 Limited data are available regarding the safety of etravirine during pregnancy. Etravirine was 
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Rathbun and Liedtke shown to be safe and effective when combined with darunavir/ ritonavir, enfuvirtide, and tenofovir/emtricitabine at 25 weeks gestation in a pregnant HIV-infected woman with multiclass resistance. Healthy twin babies were delivered at 34 weeks gestation and remained seronegative after 4 months. Cord blood collected at delivery revealed detectable levels of etravirine. 61 The safety and pharmacokinetics of etravirine were examined in 5 women who received etravirine as part of compassionate use programs. Three women began etravirine with other antiretroviral therapy during the first trimester and the other 2 in the third trimester. With the exception of one preterm delivery of twin babies by caesarian section, the remaining 4 women delivered at term (2 caesarian and 2 vaginal). One baby was born with a minor ear malformation, but all children were born healthy and remained HIV seronegative. Etravirine pharmacokinetics during pregnancy were consistent with nonpregnant adults. 62 Use of etravirine and darunavir/ritonavir in the second and third trimesters, respectively, is being examined in an ongoing pharmacokinetic study.
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Health-related quality of life
The DUET-1 and DUET-2 trials included an examination of health-related quality of life as measured by the Functional Assessment of HIV Infection questionnaire. Baseline and 24-week results of the questionnaire were compared. The 47 items in the questionnaire are grouped into 5 subscales, but only the Physical Well-Being and Functional and Global Well-Being scales were analyzed. A total of 1,203 patients were included in the analysis (n = 599 etravirine, n = 604 placebo). Statistically significant improvement in both Physical Well-Being and Functional and Global Well-Being scales were seen in the etravirine-treated group at week 24 compared with baseline (P , 0.0001 and P = 0.0003, respectively). Compared with the placebo group, these differences remained statistically greater for both measures (P = 0.01 for Physical Well-Being; P = 0.03 for Functional and Global Well-Being).
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Dosage and administration
Etravirine is presently approved for combination therapy with other antiretroviral agents in adult HIV-infected individuals with documented or suspected resistance to first-generation NNRTIs. It is available as the 100 mg F060 tablet in the recommended dose of 200 mg twice daily following a meal. The tablets can also be dispersed in a glass of water if patients have difficulty swallowing the tablet. The glass should be rinsed several times to assure the entire dose is achieved. It should be noted that unlike the NNRTI, efavirenz, the activity of etravirine in combination with 2 NRTIs for treatment-naive individuals is not presently established.
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Conclusion
Etravirine is the first second-generation NNRTI and possesses potent activity against HIV-1 strains that display resistance to first-generation NNRTI agents. The most common adverse effect is the development of rash. Etravirine is currently indicated only for use in combination therapy for antiretroviral treatment-experienced patients with documented or suspected resistance to first-generation NNRTIs. Drug interactions with some antiretrovirals can preclude use of etravirine in some antiretroviral regimens.
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